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A large phase 3 trial of the RTS,S/AS01 malaria vaccine showed moderate efficacy against 
severe and uncomplicated malaria1 but also raised a number of safety concerns.1,2 For these 
reasons, WHO recommended three, large scale pilot implementation studies3 which are 
now underway.4  Infants and children recruited to the phase 3 trial were followed for an 
initial period of three or four years respectively and it is uncertain whether the efficacy 
observed in the trial would be sustained. Two recent studies provide further information on 
the longer term efficacy and safety of RTS,S/AS01. 
In Kenya, Olotu and colleagues followed children who had been enrolled in a small phase 2 
RTS,S/AS01 trial for a period of  seven years.5 These children had received three doses of 
RTS,S/AS01 when aged 5-17 months but not the booster dose. Vaccine efficacy (VE) against 
clinical  episodes of malaria seen initially 6 was lost during the later period of  follow-up and 
in year five  there was a negative efficacy of -34.4% [95% CI-83.9, 1.8] in the overall cohort 
and of -56.8% [95% CI -118,7, -12.3] among children who lived in the area with the highest 
malaria transmission.5   
In Lancet Infectious Diseases Tinto and colleagues report findings among children enrolled in 
three of the phase 3 trial centres who were followed for an additional  three years.7 
Encouragingly, VE against severe malaria was sustained; VE against severe malaria during  
the six or seven-year post vaccination period in children who had received a booster dose 
was 36.7% [95% CI 14.6, 53.1] in the older age group  and 31.0% [95% CI 4.7, 50.0] in the 
younger age group.  VE against uncomplicated malaria during the full follow-up period was 
less 23.7% [95% CI 15.9, 30.7] and 15.5% [95% CI 6.7, 23.5] in the older and younger age 
groups respectively.  No protection against clinical malaria was seen during the extension 
period and in  the centre with the highest transmission, a statistically significant increase in 
the incidence of clinical malaria was seen in older children during the extension period (VE -
30.3% [95%CI -59.5, -6.4]). Fifteen deaths were recorded in RTS,S/AS01 vaccinated children 
(10 female, 5 male) and 7 in the controls (4 female, 3 male). Five cases of meningitis were 
reported, two in RTS,S/AS01 recipients and three in controls. Weaknesses of the study 
include a gap of nearly two years during which surveillance data was dependent on 
retrospective analysis of routinely collected data and the fact that only 70% of children in 
the original trial were enrolled in the extended follow-up.  Nevertheless, this study provides 
strong evidence that RTS,S/AS01 can provide sustained protection against severe malaria  
and some reassurance on its safety, although numbers of serious adverse events and deaths 
were small and a gender imbalance was present in the latter.    
In both studies, an increase in the incidence of uncomplicated clinical malaria was seen 
during the extended follow-up period, the effect being most marked in children exposed to 
the highest level of malaria transmission. This was not the case for severe malaria, although 
in Kenya, the peak age incidence of severe malaria was delayed in RTS,S/AS01 vaccinated 
children.  These findings are not surprising as there is strong evidence that repeated 
exposure to malaria is necessary to establish and sustain naturally acquired immunity 
although the intensity of infection needed to induce and sustain naturally acquired 
immunity is not known. However, some information comes from studies of 
chemoprevention. When malaria was prevented in Tanzanian infants during the first year of 
life a significant increase in cases of clinical malaria were seen in the following year.8 
However, in children age 3-59 months protected for one year by seasonal malaria 
chemoprevention there was only a small increase in cases of uncomplicated malaria during 
the following year.9,10 Longer periods of protection may be followed by a substantial, 
although short-lasing, increase in susceptibility to clinical malaria 11 but in all cases the 
benefits of protection exceeded those of the subsequent period of enhanced risk. It is likely 
that a highly effective malaria vaccine that provides only a relatively short period of 
protection will lead to some degree of ‘rebound malaria’ as its efficacy wanes unless the 
force of infection has been reduced during the period of follow-up. Booster vaccinations 
may delay the period of risk but vaccinated subjects may need to be provided with 
additional support during the period of enhanced risk through education, improved access 
to treatment and regular distribution of ITNs.  
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